Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | IAPP | P10997 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1452942 | 0.84 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAHPGDDAO | |
| SCHEMBL815719 | 0.83 | LIPG (0.39) | HPGDALOX5PTGS2 | |
| SCHEMBL817803 | 0.80 | LIPG (0.49) | ALOX5PTGS2 | |
| SCHEMBL11333647 | 0.80 | LIPG (0.49) | ALOX5PTGS2 | |
| SCHEMBL10354084 | 0.80 | LIPG (0.49) | ALOX5PTGS2 | |
| SCHEMBL815912 | 0.80 | PRKCI (0.32) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL135178 | 0.79 | LIPG (0.36) | KDM4EALDH1A1GAAHPGDDAO | |
| SCHEMBL16950488 | 0.78 | GRM5 (0.36) | DAOGABRA1GABRB2GRM5TSHR | |
| SCHEMBL198835 | 0.77 | DAO (0.36) | KDM4EALDH1A1GAAHPGDDAO | |
| SCHEMBL8090798 | 0.77 | GABRA1 (0.46) | KDM4EALDH1A1GAAHPGDDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008029278-A2 | CONJUGATES OF ANTITHROMBIN BINDING OLIGOSACCHARIDE DERIVATIVES AND THERAPEUTIC PROTEINS | ENDOTIS PHARMA S.A. (FR) | 2008-03-13 | — | — | WO | claimed |
| EP-1886696-A1 | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins | Endotis Pharma (FR) | 2008-02-13 | — | — | EP | claimed |
| WO-2007135417-A1 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-11-29 | — | — | WO | claimed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | claimed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | claimed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-11931415-B2 | Ophthalmic compositions | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-03-19 | — | — | US | disclosed |
| EP-3496760-B1 | OPHTHALMIC COMPOSITIONS | UNIV LIVERPOOL (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | disclosed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021072473-A1 | ANTIMICROBIALS AS FEED PRESERVATIVES | IRP Health Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
| WO-2005105864-A1 | HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-4133830-A | RECYCLING BY-PRODUCTS TO SUCCESSIVE RUNS TO IMPROVE YIELD | STAUFFER CHEMICAL COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4130583-A | AUTOGENOUS PRESSURE | STAUFFER CHEMICAL COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | KDM4E 1922/4885ALDH1A1 3471/4885GAA 2366/4885 |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | KDM4E 1868/4885ALDH1A1 2181/4885GAA 1882/4885 |
| US-11931415-B2 | Ophthalmic compositions | CRYAB, CRYAA, PDE6D | KDM4E 3404/4885ALDH1A1 1241/4885GAA 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.